Luspatercept and Imetelstat Clinical Roles Clarified for Myelodysplastic Syndromes at ASH 2025
Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting.
Abstract
Real-world data on luspatercept in lower-risk MDS and efficacy of imetelstat in transfusion-dependent and advanced MDS were presented at ASH 2025, clarifying their clinical utility.